Inspra (Eplerenone)

Eplerenone works by selectively blocking the mineralocorticoid (aldosterone) receptor in the kidneys and heart. This inhibition reduces sodium reabsorption and potassium loss, leading to increased excretion of water and sodium, lower blood pressure, and decreased cardiac workload.

The appropriate dose of Inspra is determined by the prescribing clinician based on the patient’s medical condition, kidney function, and potassium levels. Dosage may be adjusted during treatment, and patients should follow the specific instructions provided by their healthcare professional.

Safety of eplerenone in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Inspra (eplerenone) is a selective aldosterone antagonist with fewer anti‑androgenic side effects compared with older agents like spironolactone. Its selectivity may result in a lower incidence of hormonal side effects, while providing comparable efficacy for hypertension and heart‑failure management.

Inspra tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability and potency throughout its shelf life.

Inspra is taken orally, usually once daily, with or without food as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe hyperkalemia, which can cause dangerous cardiac arrhythmias, and acute renal impairment. Patients should have regular monitoring of serum potassium and kidney function, and any signs of severe electrolyte imbalance should prompt immediate medical evaluation.

Inspra should be avoided in patients with known hypersensitivity to eplerenone, severe renal impairment, or significant hyperkalemia. It is also contraindicated in individuals taking other potassium‑sparing agents without careful monitoring, and in those with severe hepatic dysfunction.